{'fraction_non_alphanumeric': 0.016363636363636365, 'fraction_numerical': 0.0018181818181818182, 'mean_word_length': 5.802469135802469, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.

Several recent clinical trials for high-grade gliomas have demonstrated promising results. Nonetheless, despite improvement in survival, these patients ultimately die of tumor progression. Malignant glioma patients are profoundly immunosuppressed, and a fundamental understanding of which types of glioma have immune resistance mediated by Tregs is required for developing and initiating specific immunotherapeutic approaches that may target these cells.